Donna L Murdaugh1,2, Alysia Bosworth3, Sunita K Patel3, Noha Sharafeldin2,4, Yanjun Chen5, Liton Francisco2, Stephen J Forman5, F Lennie Wong3, Smita Bhatia1,2. 1. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama. 2. Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama. 3. Department of Population Sciences, City of Hope, Duarte, California. 4. Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 5. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Abstract
BACKGROUND: Cognitive impairment in survivors of blood or bone marrow transplantation (BMT) is well documented. However, to the authors' knowledge, the clinical relevance of self-endorsed cognitive problems and their relation to objectively assessed cognitive impairment is not known. METHODS: The authors assessed cognitive impairment in 378 BMT recipients (median age, 52.2 years, 40% of whom were female and 68% of whom were non-Hispanic white) and 98 healthy controls at 5 predetermined time points: at baseline (before BMT) and at 6 months, 1 year, 2 years, and 3 years after BMT. Self-endorsed cognitive problems were evaluated using the Neuropsychological Impairment Scale (NIS) and correlated with a standardized 2-hour battery of objective cognitive testing at each time point. The authors examined the magnitude of difference in self-endorsed cognitive problems between BMT recipients and healthy controls, and the rate of change in scores over time. Multivariable analyses were used to identify clinical and/or demographic variables associated with self-endorsed cognitive problems. The authors also examined the association between cognitive impairment and returning to work after BMT. RESULTS: Compared with healthy controls, BMT recipients endorsed more cognitive problems (P < .001) at all time points, and the rate of change in NIS scores was found to be significantly greater in BMT recipients. Fatigue was associated with greater endorsement of cognitive problems at 1 year after BMT (odds ratio, 4.23; 95% CI, 2.1-8.3 [P < .001]). Overall, there was a statistically significant, modest correlation noted between self-endorsed cognitive problems and objective cognitive impairment (range, 0.401-0.445 [P ≤ .01]). Higher self-endorsed cognitive problems were associated with a 3.7-fold (P = .02) higher odds of not returning to work at 3 years after BMT. CONCLUSIONS: The results of the current study demonstrated that self-endorsed cognitive problems can help to identify vulnerable patient subpopulations for detailed cognitive assessment and possible cognitive remediation.
BACKGROUND:Cognitive impairment in survivors of blood or bone marrow transplantation (BMT) is well documented. However, to the authors' knowledge, the clinical relevance of self-endorsed cognitive problems and their relation to objectively assessed cognitive impairment is not known. METHODS: The authors assessed cognitive impairment in 378 BMT recipients (median age, 52.2 years, 40% of whom were female and 68% of whom were non-Hispanic white) and 98 healthy controls at 5 predetermined time points: at baseline (before BMT) and at 6 months, 1 year, 2 years, and 3 years after BMT. Self-endorsed cognitive problems were evaluated using the Neuropsychological Impairment Scale (NIS) and correlated with a standardized 2-hour battery of objective cognitive testing at each time point. The authors examined the magnitude of difference in self-endorsed cognitive problems between BMT recipients and healthy controls, and the rate of change in scores over time. Multivariable analyses were used to identify clinical and/or demographic variables associated with self-endorsed cognitive problems. The authors also examined the association between cognitive impairment and returning to work after BMT. RESULTS: Compared with healthy controls, BMT recipients endorsed more cognitive problems (P < .001) at all time points, and the rate of change in NIS scores was found to be significantly greater in BMT recipients. Fatigue was associated with greater endorsement of cognitive problems at 1 year after BMT (odds ratio, 4.23; 95% CI, 2.1-8.3 [P < .001]). Overall, there was a statistically significant, modest correlation noted between self-endorsed cognitive problems and objective cognitive impairment (range, 0.401-0.445 [P ≤ .01]). Higher self-endorsed cognitive problems were associated with a 3.7-fold (P = .02) higher odds of not returning to work at 3 years after BMT. CONCLUSIONS: The results of the current study demonstrated that self-endorsed cognitive problems can help to identify vulnerable patient subpopulations for detailed cognitive assessment and possible cognitive remediation.
Authors: Grant R Williams; Kelly M Kenzik; Mariel Parman; Mustafa Al-Obaidi; Liton Francisco; Gabrielle B Rocque; Andrew McDonald; Ravi Paluri; Rudolph M Navari; Lakshmin Nandagopal; Olumide Gbolahan; Crystal Young-Smith; Matthew Robertson; Smita Bhatia Journal: J Geriatr Oncol Date: 2019-04-18 Impact factor: 3.599
Authors: Natalie L Wu; Amanda I Phipps; Kevin R Krull; Karen L Syrjala; Paul A Carpenter; Laura S Connelly-Smith; Mary E Flowers; Elizabeth F Krakow; Masumi Ueda Oshima; Stephanie J Lee; Eric J Chow Journal: Blood Adv Date: 2022-07-26
Authors: Lakshmanan Krishnamurti; Staci D Arnold; Ann Haight; Allistair Abraham; Gregory Mt Guilcher; Tami John; Nitya Bakshi; Shalini Shenoy; Karen Syrjala; Paul L Martin; Sonali Chaudhury; Gretchen Eames; Olusola Festus Olowoselu; Matthew Hsieh; Josu De La Fuente; Kimberly A Kasow; Elizabeth Stenger; Anne Mertens; Fuad El-Rassi; Peter Lane; Bronwen E Shaw; Lillian Meacham; David Archer Journal: JMIR Res Protoc Date: 2022-07-06
Authors: Rebecca A Harrison; Noha Sharafeldin; Jennie L Rexer; Brennan Streck; Melissa Petersen; Ashley M Henneghan; Shelli R Kesler Journal: Oncologist Date: 2021-07-12